| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| EPSC | excitatory postsynaptic current |
|---|---|
| EPSP | excitatory postsynaptic potential |
| IPSC | inhibitory postsynaptic current |
| IPSP | inhibitory postsynaptic potential |
| PSD | particle size distribution; peptone, starch, and dextrose; periodic synchronous discharge; phase-sen... |
| EPSC | Excitatory postsynaptic current |
|---|---|
| f-EPSPs | Fast excitatory postsynaptic potentials |
| fEPSP | Field excitatory postsynaptic potential |
| IPSPs | inhibitor postsynaptic potentials |
| MEPSP | Miniature excitatory postsynaptic potential |
| postsynaptic | Pertaining to the area on the distal side of a synaptic cleft. (05 Mar 2000) |
|---|---|
| postsynaptic cell | In a chemical synapse, the cell that receives a signal (binds neurotransmitter) from the presynaptic cell and responds with depolarisation In an electrical synapse, the postsynaptic cell would just be downstream, but since many electrical synapses are rectifying, one of the two cells involved will always be postsynaptic. (18 Nov 1997) |
| postsynaptic membrane | That part of the plasma membrane of a neuron or muscle fibre with which an axon terminal forms a synaptic junction; in many instances, at least part of such a small postsynaptic membrane patch shows characteristic morphological modifications such as greater thickness and higher electron-density, believed to correspond to the transmitter-sensitive receptor site of such synapses. (05 Mar 2000) |
| postsynaptic potential | In a synapse, a change in the resting potential of a postsynaptic cell following stimulation of the presynaptic cell. For example: in a cholinergic synapse, the release of acetylcholine from the presynaptic cell causes channels to open in the postsynaptic cell. Each channel opening causes a small depolarisation, known as a miniature end plate potential (mepp), these sum to produce an excitatory postsynaptic potential. (18 Nov 1997) |
| inhibitory postsynaptic potential | The change in potential produced in the membrane of the next neuron when an impulse which has an inhibitory influence arrives at the synapse; it is a local change in the direction of hyperpolarization; the frequency of discharge of a given neuron is determined by the extent to which impulses that lead to excitatory postsynaptic potential's predominate over those that cause inhibitory postsynaptic potential's. (05 Mar 2000) |
| excitatory postsynaptic potential | The change in potential which is produced in the membrane of the next neuron when an impulse which has an excitatory influence arrives at the synapse; it is a local change in the direction of depolarisation; summation of these potential's can lead to discharge of an impulse by the neuron. (05 Mar 2000) |
| excitatory postsynaptic potentials | The change in potential produced in the membrane of the next neuron when an impulse which has an excitatory influence arrives at the synapse; it is a local change in the direction of depolarisation; summation of these potentials can lead to discharge of an impulse by the neuron. (12 Dec 1998) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |
| auditory receptor cells | Columnar cell's in the epithelium of the organ of Corti, having hairs (stereocilia) on their apical ends. See: Corti's cells. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor kinase | <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor Registry number: EC 2.7.1.- Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2 (26 Jun 1999) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|